Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» CAR-T
CAR-T
New Novartis CEO Narasimhan will face plenty of obstacles despite CAR-T triumph
Fierce Biotech
Tue, 09/5/17 - 11:10 am
Novartis
Pharma CEOs
Vas Narasimhan
CAR-T
Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR-T
Xconomy
Tue, 09/5/17 - 09:50 am
FDA
Cellectis
CAR-T
UCART123
clinical trials
Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better
Motley Fool
Tue, 09/5/17 - 09:28 am
Gilead Sciences
CAR-T
Kite Pharma
M&A
Novartis follows up on big CAR-T win by naming Vas Narasimhan as its new CEO
Endpoints
Mon, 09/4/17 - 10:13 am
Novartis
Pharma CEOs
CAR-T
Vas Narasimhan
Joe Jimenez
At $475,000, new cancer drug raises thorny questions about drug pricing — and value
Stat
Mon, 09/4/17 - 10:11 am
drug pricing
CAR-T
Novartis
Kymriah
3 Biotech Stocks That Skyrocketed This Past Week
Motley Fool
Mon, 09/4/17 - 10:07 am
Abeona Therapeutics
EB-101
Sangamo BioSciences
SB-525
Juno Therapeutics
CAR-T
Takeda partners with Noile-Immune on next-gen CAR-T pipeline for solid tumors
Endpoints
Mon, 09/4/17 - 10:05 am
Takeda
Noile-Immune
CAR-T
solid tumors
Neurotoxicity kills a CAR-T rival pushed by J&J, MacroGenics in $700M deal
Endpoints
Fri, 09/1/17 - 11:31 pm
JNJ
CAR-T
Macrogenics
MGD011
Landmark approval won, Novartis' next test is scaling CAR-T manufacturing
BioPharma Dive
Fri, 09/1/17 - 11:24 am
Novartis
CAR-T
Kymriah
FDA
drug manufacturing
Profit on $475,000 Novartis cancer drug could be a while coming
Yahoo/Reuters
Fri, 09/1/17 - 11:15 am
Novartis
CAR-T
Kymriah
Why bluebird bio Inc Continued Its March Higher Again Today
Motley Fool
Thu, 08/31/17 - 10:13 pm
Bluebird Bio
bb2121
CAR-T
Novartis
Kymriah
Gilead Sciences
Kite Pharma
Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences
Motley Fool
Thu, 08/31/17 - 10:11 pm
Novartis
CAR-T
Kymriah
Gilead Sciences
Kite Pharma
M&A
A Cancer Doc Weighs In On CAR-T, Precision Medicine And Pricing Debates
Forbes
Thu, 08/31/17 - 09:17 am
CAR-T
precision medicine
drug pricing
Novartis
Kymriah
Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?
Forbes
Wed, 08/30/17 - 11:53 pm
Novartis
CAR-T
drug pricing
FDA
acute lymphoblastic leukemia
Kymriah
Joe Jimenez
Novartis Wins Historic FDA Nod, Prices CAR-T For Leukemia at $475,000
Xconomy
Wed, 08/30/17 - 11:48 pm
Novartis
FDA
CAR-T
drug pricing
Kymriah
acute lymphoblastic leukemia
Has Gilead Sciences' Big Bounce Begun With the Kite Pharma Buyout?
Motley Fool
Wed, 08/30/17 - 10:04 am
Gilead Sciences
CAR-T
Kite Pharma
M&A
How will Gilead price CAR-T? With Kite buy, the top biotech joins Novartis in spotlight
Fierce Pharma
Tue, 08/29/17 - 09:07 pm
Gilead Sciences
Kite Pharma
CAR-T
drug pricing
M&A
Here's What Else Gilead Sciences Gets by Buying Kite Pharma
Motley Fool
Tue, 08/29/17 - 10:01 am
Gilead Sciences
Kite Pharma
M&A
CAR-T
TCR-targeted drugs
To Be More Than a Quick Splash, Gilead’s CAR-T Purchase Faces Hurdles
Xconomy
Tue, 08/29/17 - 01:12 pm
Gilead Sciences
Kite Pharma
M&A
CAR-T
5 Reasons The Gilead-Kite Acquisition Might Work
Seeking Alpha
Mon, 08/28/17 - 10:47 pm
Gilead Sciences
M&A
Kite Pharma
CAR-T
Pages
« first
‹ previous
…
15
16
17
18
19
20
21
22
23
…
next ›
last »